
Parabilis reports 72% response rate for desmoid tumor drug
Parabilis Medicines (Nasdaq: PBLS) presented updated Phase 1/2 clinical data for its investigational drug zolucatetide in desmoid tumor patients at the European Society for Medical Oncology Congress on Oct. 24, 2026, in Madrid, Spain.
Among response-evaluable patients who began treatment at a starting dose of 450 mg or higher, the drug showed an objective response rate of 72.2% (13 of 18 patients) in a 32-week landmark analysis, based on a June 22, 2026, data cutoff. A disease control rate of 100% was observed across all 46 response-evaluable patients receiving that starting dose, with no disease progression recorded.
As of the data cutoff, 76 patients had been enrolled and treated across all dose levels. Median age was 37 years, and 69.7% of patients were female. Treatment-related adverse events were predominantly low-grade, with fatigue, alopecia, and nausea most commonly reported. No patients discontinued treatment due to treatment-related adverse events.
Data from a three-arm ra











%3Amax_bytes(150000)%3Astrip_icc()%2F1969-62ed5cccb7fd4fdeb66c4544c5c7a84d.png&w=3840&q=75)


%3Amax_bytes(150000)%3Astrip_icc()%2FGettyImages-2301313271-2bc630d688d94069b5dfbc512774c219.jpg&w=3840&q=75)


%3Amax_bytes(150000)%3Astrip_icc()%2FGettyImages-2297144179-327f8142f8ae43f7b45c6e6ac1160999.jpg&w=3840&q=75)